EIKN Eikon Therapeutics, Inc. - Common Stock
$11.00
Price · May 20, 2026
Fundamentals as of May 11, 2026
52W Range
$8–$17
33% of range
Analyst Rating
BUY
12 analysts
Price Target
$30
+175% upside
P/E (TTM)
—
ROE
—
Net Profit Margin
—
EIKN Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
Price
$10.99
Market Cap
—
P/E (TTM)
—
EPS (TTM)
—
Revenue (TTM)
—
Div Yield
—
ROE
—
Debt/Equity
—
52W Range
$8 – $17
EIKN Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
Configure
10-Year Performance Revenue, net income, margins and EPS trends
Revenue & Net Income
—
EPS
—
Free Cash Flow
—
Margins
—
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
Metric
5Y trend
EIKN
Peer Median
Profitability Gross, operating and net margins; ROE, ROA, ROIC
Metric
5Y trend
EIKN
Peer Median
Financial Health Debt, liquidity, solvency — balance sheet strength
Metric
5Y trend
EIKN
Peer Median
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
Metric
5Y trend
EIKN
Peer Median
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
Metric
5Y trend
EIKN
Peer Median
EIKN Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
BUY
12 analysts
- Strong Buy 3 25.0%
- Buy 7 58.3%
- Hold 1 8.3%
- Sell 0 0.0%
- Strong Sell 1 8.3%
12-Month Price Target
4 analysts · 2026-05-18
Median
$30.50
← Below all targets
$10.99
Low
$26.00
High
$34.00
Median target
$30.50
+177.4%
Mean target
$30.25
+175.1%
Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
Avg Surprise
-0.68%
| Period | EPS Actual | EPS Est | Surprise |
|---|---|---|---|
| March 31, 2026 | $-2.46 | $-1.78 | -0.68% |
Peer Comparison Key metrics vs sector peers
| Ticker | Market Cap | P/E | Rev YoY | Net Margin | ROE | Gross Margin |
|---|---|---|---|---|---|---|
| EIKN | — | — | — | — | — | — |
| ALLO | $314M | -1.6 | -76.8% | — | -59.9% | — |
| IRWD | $550M | 22.5 | -15.7% | 8.1% | -8.5% | — |
| SLDB | $445M | -2.8 | — | — | -79.5% | — |
| GYRE | $645M | 353.0 | 10.2% | 8.5% | 11.7% | — |
| TRAX | — | — | — | — | — | — |
| CADL | $310M | -7.8 | — | — | -53.7% | — |
| CLYM | $191M | -4.5 | — | — | -34.6% | — |
| CABA | $220M | -1.0 | — | — | -115.5% | — |
| KYTX | $568M | -2.6 | — | — | -77.4% | — |
| MDXG | $1.00B | 21.2 | 20.0% | 11.6% | 20.5% | 82.6% |
Full Fundamentals All metrics by year — income statement, balance sheet, cash flow
Balance Sheet 18
| Metric | Trend | 2025 |
|---|---|---|
| Cash & Equivalents | $105M | |
| Short-term Investments | $231M | |
| Prepaid Expense | $13M | |
| Current Assets | $349M | |
| PP&E (Net) | $143M | |
| PP&E (Gross) | $186M | |
| Accum. Depreciation | $43M | |
| Other Non-current Assets | $4M | |
| Total Assets | $595M | |
| Accounts Payable | $681.0K | |
| Current Liabilities | $55M | |
| Capital Leases | $247M | |
| Other Non-current Liabilities | $10M | |
| Total Liabilities | $312M | |
| Retained Earnings | $-921M | |
| Stockholders' Equity | $-879M | |
| Liabilities + Equity | $595M | |
| Shares Outstanding | 3,068,490 |
Income Statement 10
| Metric | Trend | Q1 2026 |
|---|---|---|
| R&D Expense | $70M | |
| SG&A Expense | $17M | |
| Operating Expenses | $87M | |
| Operating Income | $-87M | |
| Net Income | $-83M | |
| EPS (Basic) | $-2.46 | |
| EPS (Diluted) | $-2.46 | |
| Shares (Basic) | 33,700,550 | |
| Shares (Diluted) | 33,700,550 | |
| EBITDA | $-87M |
Balance Sheet 19
| Metric | Trend | Q1 2026 |
|---|---|---|
| Cash & Equivalents | $161M | |
| Short-term Investments | $351M | |
| Prepaid Expense | $17M | |
| Current Assets | $530M | |
| PP&E (Net) | $138M | |
| PP&E (Gross) | $186M | |
| Accum. Depreciation | $48M | |
| Other Non-current Assets | $556.0K | |
| Total Assets | $851M | |
| Accounts Payable | $6M | |
| Current Liabilities | $45M | |
| Capital Leases | $245M | |
| Other Non-current Liabilities | $10M | |
| Total Liabilities | $300M | |
| Common Stock | $5.0K | |
| Retained Earnings | $-1.00B | |
| Stockholders' Equity | $551M | |
| Liabilities + Equity | $851M | |
| Shares Outstanding | 54,138,555 |
Cash Flow 8
| Metric | Trend | Q1 2026 |
|---|---|---|
| Stock-based Comp | $3M | |
| Operating Cash Flow | $-90M | |
| CapEx | $262.0K | |
| Investing Cash Flow | $-203M | |
| Stock Issued | $277.0K | |
| Net Stock Activity | $277.0K | |
| Financing Cash Flow | $349M | |
| Free Cash Flow | $-90M |
Profitability 5
| Metric | Trend | Q1 2026 |
|---|---|---|
| Operating Margin | -1994.0% | |
| Net Margin | -1894.0% | |
| EBITDA Margin | -1994.0% | |
| ROA | -19.5% | |
| ROE | -30.1% |
Liquidity & Solvency 2
| Metric | Trend | Q1 2026 |
|---|---|---|
| Current Ratio | 11.8 | |
| Quick Ratio | 11.4 |
Efficiency 1
| Metric | Trend | Q1 2026 |
|---|---|---|
| Asset Turnover | 0.0 |
Valuation (TTM) 5
| Metric | Trend | Q1 2026 |
|---|---|---|
| Market Cap | $573M | |
| P/B | 1.0 | |
| P / Tangible Book | 1.0 | |
| P / Cash Flow | -6.4 | |
| P / FCF | -6.4 |
Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years
My Metrics Your personal watchlist — selected rows from Full Fundamentals
📊
Pick the metrics that matter to you — click the ➕ next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.